BIOPLATE, INC. – Trademark Portfolio

Entity Type: 03

BIOPLATE, INC. holds 25 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 10 (Medical Apparatus) — 24 filings in this category. The portfolio also extends into Class 40 (Treatment & Processing) across 2 Nice Classification classes. Currently, 9 trademarks are registered and 1 is pending. Notable registered marks include MAXFAX, BIOMESH, BIOPLATE, CRANIOFIT, and BIOPLATE XPRESS. The owner is based in Placentia, CA.

570 Melrose Ave.

Placentia, CA 92870

25 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Page 1 of 2 (25 results)

Trademark Classifications

BIOPLATE, INC.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

10
Medical Apparatus (24 filings)

Surgical, medical, dental and veterinary apparatus and instruments

40
Treatment & Processing (1 filing)

Treatment of materials

Frequently Asked Questions

How many trademarks does BIOPLATE, INC. have?

BIOPLATE, INC. has 25 U.S. trademarks filed with the USPTO. Of these, 9 registered, 1 pending, 5 abandoned, 10 cancelled.

What trademark classes does BIOPLATE, INC. file in?

BIOPLATE, INC. files trademarks across 2 Nice Classification classes. The most active classes are Class 10 (Medical Apparatus), Class 40 (Treatment & Processing). Class 10 covers surgical, medical, dental and veterinary apparatus and instruments.

What are BIOPLATE, INC.'s most well-known trademarks?

BIOPLATE, INC.'s registered trademark portfolio includes well-known marks such as MAXFAX, BIOMESH, BIOPLATE, CRANIOFIT, and BIOPLATE XPRESS. These are among 9 currently registered trademarks in the portfolio.

What is BIOPLATE, INC.'s trademark registration success rate?

BIOPLATE, INC. has a 38% trademark registration rate, with 9 out of 24 resolved applications resulting in successful registration. Currently, 1 application is pending review.